CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$235.03M, lower than 95% of all stocks globally
- PositionPrice-to-book is 1×, lower than 95% of its Biotechnology peers (median 4.48×)
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.67%Above 5Y avg (0.53%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
44.0%Sustainable
Last Ex-Dividend
Jun 24, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
32.24BCNY4.83B · vs all stocks (USD)
Trailing P/E
25.58xvs Biotechnology peers
Revenue (TTM)
6.61BCNY989.10M · vs all stocks (USD)
Profit Margin
18.29%vs Biotechnology peers
Beta
0.2700xvs all stocks
52-Week Change
-26.69%vs all stocks
Market Capitalization
32.24BCNY4.83B · vs all stocks (USD)
Enterprise Value
33.39BCNY5.00B · vs all stocks (USD)
Trailing P/E
25.58xvs Biotechnology peers
Forward P/E
13.50xvs Biotechnology peers
Price to Sales (TTM)
4.85xvs Biotechnology peers
Price to Book (MRQ)
0.9963xvs Biotechnology peers
Enterprise to Revenue
5.05xvs Biotechnology peers
Enterprise to EBITDA
23.49xvs Biotechnology peers
Gross Margin
32.92%vs Biotechnology peers
Profit Margin
18.29%vs Biotechnology peers
Operating Margin
14.50%vs Biotechnology peers
Return on Assets (TTM)
1.94%vs Biotechnology peers
Return on Equity (TTM)
3.73%vs Biotechnology peers
Revenue (TTM)
6.61BCNY989.10M · vs all stocks (USD)
Revenue per Share (TTM)
1.01CNYUpdated Oct 19, 2026Quarterly Revenue Growth
-12.70%vs Biotechnology peers
Gross Profit (TTM)
2.34BCNY350.23M · vs all stocks (USD)
EBITDA (TTM)
1.69BCNY252.98M · vs all stocks (USD)
Net Income (TTM)
1.21BCNY180.94M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.50%vs Biotechnology peers
Operating Cash Flow (TTM)
-662.81MCNY-99.25M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.57BCNY-235.03M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0330CNYUpdated Oct 19, 2026Trailing Annual Dividend Yield
0.67%vs all stocks
5-Year Average Dividend Yield
0.53%vs all stocks
Payout Ratio
43.95%vs Biotechnology peers
Revenue
7.35BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
4.60BCNYFY2025 · Dec 31, 2025Gross Profit
2.75BCNYFY2025 · Dec 31, 2025Operating Income
1.68BCNY251.36M · vs all stocks (USD)
Pre-tax Income
1.91BCNYFY2025 · Dec 31, 2025Income Tax Expense
328.93MCNYFY2025 · Dec 31, 2025Net Income
1.58BCNYFY2025 · Dec 31, 2025EBIT
1.95BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.34BCNYFY2025 · Dec 31, 2025Research & Development
223.37MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
334.95MCNYFY2025 · Dec 31, 2025Other Operating Expenses
48.63MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
69.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
44.11MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
6.57BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
6.57BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.58BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
418.92KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
398.55MCNYFY2025 · Dec 31, 2025Free Cash Flow
22.73MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.34BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.58BCNYFY2025 · Dec 31, 2025Stock-based Compensation
19.80MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-23.64MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-387.33MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-786.88MCNYFY2025 · Dec 31, 2025Capital Expenditures
-375.82MCNYFY2025 · Dec 31, 2025Net Acquisitions
-3.70BCNYFY2025 · Dec 31, 2025Purchase of Investments
-492.76MCNYFY2025 · Dec 31, 2025Sale of Investments
2.32BCNYFY2025 · Dec 31, 2025Other Investing Activity
-392.53KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.25BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
3.66BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-295.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-258.58MCNYFY2025 · Dec 31, 2025Other Financing Charges
-538.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
2.57BCNYFY2025 · Dec 31, 2025Shares Outstanding
6.59BSharesUpdated Oct 19, 2026Float Shares
4.48BSharesUpdated Oct 19, 2026% Held by Insiders
32.47%vs all stocks
% Held by Institutions
22.79%vs all stocks
Total Cash (MRQ)
2.44BCNY364.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3670CNYUpdated Oct 19, 2026Total Debt (MRQ)
3.54BCNY529.68M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1091xvs Biotechnology peers
Current Ratio (MRQ)
4.49xvs Biotechnology peers
Book Value per Share (MRQ)
4.88CNYUpdated Oct 19, 2026Total Assets
37.78BCNY5.66B · vs all stocks (USD)
Total Current Assets
9.95BCNYFY2025 · Dec 31, 2025Total Liabilities
5.33BCNYFY2025 · Dec 31, 2025Total Non-current Assets
27.83BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.59BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.74BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.40BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.84BCNYFY2025 · Dec 31, 2025Inventory
5.37BCNYFY2025 · Dec 31, 2025Accounts Payable
343.02MCNYFY2025 · Dec 31, 2025Short-term Debt
1.43BCNYFY2025 · Dec 31, 2025Other Current Liabilities
142.66KCNYFY2025 · Dec 31, 2025Long-term Debt
2.48BCNYFY2025 · Dec 31, 2025Common Stock (Book)
6.64BCNYFY2025 · Dec 31, 2025Retained Earnings
11.02BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
32.46BCNY4.86B · vs all stocks (USD)
Treasury Stock
522.95MCNYFY2025 · Dec 31, 202552-Week Low
4.18CNYUpdated Oct 19, 202652-Week High
6.97CNYUpdated Oct 19, 202652-Week Change
-26.69%vs all stocks
Beta
0.2700xvs all stocks
50-Day MA
5.00CNYUpdated Oct 19, 2026200-Day MA
5.46CNYUpdated Oct 19, 2026Avg 10-Day Volume
68.55MSharesUpdated Oct 19, 2026Avg 30-Day Volume
48.25MSharesUpdated Oct 19, 2026Diluted EPS (TTM)
0.1900CNYUpdated Oct 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1×, lower than 95% of its Biotechnology peers (median 4.48×)Notable
Price-to-book: 1.00Industry median: 4.48Industry P5: 1.30Peers compared: 184
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 180,937,535.977Operating Cash Flow (USD, TTM): -99,248,620.753
Financial Health
Altman Z-Score 4.63: safe zoneNotable
Altman Z-Score: 4.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$235.03M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -235,025,291.482Global P5: -208,569,634.4
Market cap is $4.83B, above the global median of $1.15BNotable
Market cap (USD): 4,827,343,636.744Global Median: 1,150,342,212.262
Revenue is $989.1M, above the global median of $559.35MNotable
Revenue (USD): 989,103,262.28Global Median: 559,350,010.583
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anthem Biosciences Limited
Tier 1ProductionApproval-Gated PipelineFlowSenseMaking
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule